AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (3.5 MB)
Collect
AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

GPCR-Gs mediates the protective effects of ginsenoside Rb1 against oxygen-glucose deprivation/re-oxygenation-induced astrocyte injury

Xi WangaYing LiuaJuan LibJiayu XieaYi DaicMinke Tanga,( )
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China
Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
School of Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan

Peer review under responsibility of Beijing University of Chinese Medicine.

Show Author Information

Abstract

Objectives

To investigate whether the protective actions of ginsenoside Rb1 (Rb1) on astrocytes are mediated through the Gs-type G-protein-coupled receptor (GPCR-Gs).

Methods

Primary astrocyte cultures derived from neonatal mouse brain were used. Astrocyte injury was induced via oxygen-glucose deprivation/re-oxygenation (OGD/R). Cell morphology, viability, lactate dehydrogenase (LDH) leakage, apoptosis, glutamate uptake, and brain-derived neurotrophic factor (BDNF) secretion were assessed to gauge cell survival and functionality. Western blot was used to investigate the cyclic adenosine monophosphate (cAMP) and protein kinase B (Akt) signaling pathways. GPCR-Gs-specific inhibitors and molecular docking were used to identify target receptors.

Results

Rb1 at concentrations ranging from 0.8 to 5 μM did not significantly affect the viability, glutamate uptake, or BDNF secretion in normal astrocytes. OGD/R reduced astrocyte viability, increasing their LDH leakage and apoptosis rate. It also decreased glutamate uptake and BDNF secretion by these cells. Rb1 had protective effects of astrocytes challenged by OGD/R, by improving viability, reducing apoptosis, and enhancing glutamate uptake and BDNF secretion. Additionally, Rb1 activated the cAMP and Akt pathways in these cells. When the GPCR-Gs inhibitor NF449 was introduced, the protective effects of Rb1 completely disappeared, and its activation of cAMP and Akt signaling pathways was significantly inhibited.

Conclusion

Rb1 protects against astrocytes from OGD/R-induced injury through GPCR-Gs mediation.

References

1

Cheng Z, Zhang M, Ling C, et al. Neuroprotective effects of ginsenosides against cerebral ischemia. Molecules. 2019;24(6):1102.

2

Li DW, Zhou FZ, Sun XC, et al. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection. Neural Regen Res. 2019;14(10):1814-1822.

3

Gao X, Zhang X, Cui L, et al. Ginsenoside Rb1 promotes motor functional recovery and axonal regeneration in post-stroke mice through cAMP/PKA/CREB signaling pathway. Brain Res Bull. 2020;15451-15460.

4

Zhang HM, Chen X, Wang X, Liu Y, Sands CD, Tang MK. Ginsenoside Rb1 attenuates lipopolysaccharide-induced neural damage in the brain of mice via regulating the dysfunction of microglia and astrocytes. J Integr Neurosci. 2021;20(4):813-823.

5

Li J, Liu YS, Liu Y, Wang X, Tang MK. Effect of intranasal ginsenoside Rb1 against epilepsy in mice induced by chronic ignition of pentylenetetrazole. Chin J Exp Tradit Med Formul. 2022;28(24):65-74 [Chinese].

6
Ma Q. Study on the Protective Effect of Ginsenoside Rb1 on Cerebral Ischemia and its Mechanism Based on the Glutamate Transport [dissertation]. Beijing, China: Beijing University of Chinese Medicine; 2022 [Chinese].
7

Xu M, Ma Q, Fan CL, Chen X, Zhang HM, Tang MK. Ginsenosides Rb1 and Rg1 protect primary cultured astrocytes against oxygen-glucose deprivation/reoxygenation-induced injury via improving mitochondrial function. Int J Mol Sci. 2019;20(23):6086.

8

Verkhratsky A, Nedergaard M. Physiology of astroglia. Physiol Rev. 2018;98(1):239-389.

9

Farizatto KLG, Baldwin KT. Astrocyte-synapse interactions during brain development. Curr Opin Neurobiol. 2023;80:102704.

10

Sanmarco LM, Polonio CM, Wheeler MA, Quintana FJ. Functional immune cell-astrocyte interactions. J Exp Med. 2021;218(9):e20202715.

11

Guillamón-Vivancos T, Gómez-Pinedo U, Matías-Guiu J. Astrocytes in neurodegenerative diseases (Ⅰ): function and molecular description. Neurologia. 2015;30(2):119-129.

12

Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-35.

13

Liu Z, Chopp M. Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol. 2016;144:103-120.

14

Kofuji P, Araque A. G-protein-coupled receptors in astrocyte-neuron communication. Neuroscience. 2021;456:71-84.

15

Rosenbaum DM, Rasmussen SGF, Kobilka BK. The structure and function of G-protein-coupled receptors. Nature. 2009;459(7245):356-363.

16

Weis WI, Kobilka BK. The molecular basis of G protein-coupled receptor activation. Annu Rev Biochem. 2018;87:897-919.

17

Liccardo F, Luini A, Di Martino R. Endomembrane-based signaling by GPCRs and G-proteins. Cells. 2022;11(3):528.

18

McCarthy KD, De Vellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol. 1980;85(3):890-902.

19

Cahoy JD, Emery B, Kaushal A, et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008;28(1):264-278.

20

Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388-D1395.

21

Rose Y, Duarte JM, Lowe R, et al. RCSB protein data bank: architectural advances towards integrated searching and efficient access to macromolecular structure data from the PDB archive. J Mol Biol. 2021;433(11):166704.

22

Seeliger D, De Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417-422.

23

Chen A, Xiong LJ, Tong Y, Mao M. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep. 2013;1(2):167-176.

24

Chen Y, Swanson RA. Astrocytes and brain injury. J Cerebr Blood Flow Metabol. 2003;23(2):137-149.

25

Molofsky AV, Deneen B. Astrocyte development: a guide for the perplexed. Glia. 2015;63(8):1320-1329.

26

Benarroch EE. Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc. 2005;80(10):1326-1338.

27

Mahmoud S, Gharagozloo M, Simard C, Gris D. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells. 2019;8(2):184.

28

Li C, Sui C, Wang W, et al. Baicalin attenuates oxygen-glucose deprivation/reoxygenation-induced injury by modulating the BDNF-TrkB/PI3K/Akt and MAPK/Erk1/2 signaling axes in neuron-astrocyte cocultures. Front Pharmacol. 2021;12:599543.

29

Campbell AP, Smrcka AV. Targeting G protein-coupled receptor signalling by blocking G proteins. Nat Rev Drug Discov. 2018;17(11):789-803.

30

Wettschureck N, Offermanns S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85(4):1159-1204.

31

Neves SR, Ram PT, Iyengar R. G protein pathways. Science. 2002;296(5573):1636-1639.

32

Bai H, Zhao L, Liu H, et al. Adiponectin confers neuroprotection against cerebral ischemia-reperfusion injury through activating the cAMP/PKA-CREB-BDNF signaling. Brain Res Bull. 2018;143:145-154.

33

Liu X, Fan L, Li J, et al. Mailuoning oral liquid attenuates convalescent cerebral ischemia by inhibiting AMPK/mTOR-associated apoptosis and promoting CREB/BDNF-mediated neuroprotection. J Ethnopharmacol. 2023;317:116731.

34

Peng M, Ling X, Song R, et al. Upregulation of GLT-1 via PI3K/Akt pathway contributes to neuroprotection induced by dexmedetomidine. Front Neurol. 2019;10:1041.

35

Li LB, Toan SV, Zelenaia O, et al. Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem. 2006;97(3):759-771.

36

Hohenegger M, Waldhoer M, Beindl W, et al. Gsalpha-selective G protein antagonists. Proc Natl Acad Sci U S A. 1998;95(1):346-351.

37

Collo G, North RA, Kawashima E, et al. Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. J Neurosci. 1996;16(8):2495-2507.

38

Liu Y, Li J, Wang X, et al. Ginsenoside Rb1 attenuates lipopolysaccharide-induced chronic neuroinflammation in mice by tuning glial cell polarization. J Tradit Chin Med Sci. 2022;9(0):383-391.

39

Shi YH, Li Y, Wang Y, Xu Z, Fu H, Zheng GQ. Ginsenoside-Rb1 for ischemic stroke: a systematic review and meta-analysis of preclinical evidence and possible mechanisms. Front Pharmacol. 2020;11:285.

40

Rajabian A, Rameshrad M, Hosseinzadeh H. Therapeutic potential of panax ginseng and its constituents, ginsenosides and gintonin, in neurological and neurodegenerative disorders: a patent review. Expert Opin Ther Pat. 2019;29(1):55-72.

41

Traylor M, Persyn E, Tomppo L, et al. Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies. Lancet Neurol. 2021;20(5):351-361.

42

Wang S, Liang R, Liu H. Phoenixin-20 ameliorates brain infarction by promoting microglia M2 polarization in an ischemic stroke model. Metab Brain Dis. 2022;37(5):1517-1526.

43

Wang XS, Yue J, Hu LN, et al. Activation of G protein-coupled receptor 30 protects neurons by regulating autophagy in astrocytes. Glia. 2020;68(1):27-43.

Journal of Traditional Chinese Medical Sciences
Pages 33-43
Cite this article:
Wang X, Liu Y, Li J, et al. GPCR-Gs mediates the protective effects of ginsenoside Rb1 against oxygen-glucose deprivation/re-oxygenation-induced astrocyte injury. Journal of Traditional Chinese Medical Sciences, 2024, 11(1): 33-43. https://doi.org/10.1016/j.jtcms.2023.11.002

156

Views

5

Downloads

0

Crossref

0

Scopus

Altmetrics

Received: 28 September 2023
Revised: 13 November 2023
Accepted: 13 November 2023
Published: 18 November 2023
© 2024 Beijing University of Chinese Medicine.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return